摘要
免疫疗法在治疗恶性肿瘤方面取得了突破性进展,为肿瘤患者带来新的希望。免疫检查点抑制剂(ICI)包括抗细胞毒性T淋巴细胞抗原4、抗程序性细胞死亡1和抗程序性细胞死亡配体1抗体。随着临床上ICI的广泛应用,其相关不良反应也逐渐显现,这些不良事件涉及消化、呼吸、血液等多个系统,现内分泌系统不良反应也逐渐被认识,需要内分泌科医生与肿瘤科医生共同合作完成相关诊疗。本文就ICI类抗肿瘤药物带来的内分泌系统不良反应及相关筛查和监测策略进行分析、讨论,以提示临床识别和治疗内分泌系统不良反应的重要性。
Immunotherapy has made breakthroughs in the treatment of malignant tumors,bringing new hopes to patients with cancer.Immunological checkpoint inhibitors include anti-cytotoxic T lymphocyte antigen 4,anti-programmed cell death 1 and anti-programmed cell death 1 ligand antibodies.As the widespread application of these drugs,the related side effects are crept in.Immune-related adverse events(irAEs)involve multiple systems such as digestion,respiration,and hematological system.The recent recognition of IrAEs in endocrine system required cooperation between endocrinologists and oncologists in diagnosis and treatment of such patients.This review outlines the various irAEs in endocrine system associated with immunological checkpoint inhibitors,as well as screening and monitoring strategies for these endocrinerelated side effects.We also highlighted the most crucial aspects of the management of the side effects in endocrine systems.
作者
刘艳
张瑞
蔡晓凌
韩学尧
纪立农
LIU Yan;ZHANG Rui;CAI Xiaoling(Department of Endocrinology,Peking University People's Hospital,Beijing 100044,China)
出处
《中国糖尿病杂志》
CAS
CSCD
北大核心
2020年第4期309-314,共6页
Chinese Journal of Diabetes
作者简介
通信作者:纪立农,Email:jiln@bjmu.edu.cn。
